Revenue Cleared the Street; the Loss Did Not
Natera's investor relations release put total revenue at $794.0 million for the quarter ended September 30, 2026, up 34.1% from $592.2 million a year earlier. Gross margin was 64.7%. The company processed about 1,093,100 tests, up 22.3%, including about 339,500 oncology tests, up 60.9%. Net loss was $59.9 million, or $0.42 per diluted share, versus a $87.5 million loss, or $0.64 per share, a year earlier. Operating expenses rose 19.5% to $576.1 million on headcount and clinical-trial spend. Cash, cash equivalents, and restricted cash were about $1,097.2 million at quarter-end.
Investing.com put Street consensus near a $0.27 loss per share and about $707.64 million of revenue, so the quarter beat on sales and missed on EPS. MarketWatch cited FactSet estimates of a $0.28 loss and $707.5 million of revenue. Full-year 2026 revenue guidance moved to $3.005 billion to $3.035 billion from $2.850 billion to $2.910 billion, a midpoint raise of about $140 million, with positive cash flow still expected and gross margin guided near 64% to 66%.
Chapman Steps Down the Same Afternoon Moshkevich Takes Over
In a separate leadership release dated November 5, 2026, Natera said Solomon Moshkevich was appointed chief executive officer and a board member effective immediately. Steve Chapman stepped down as CEO and will remain a consultant and an adviser to the board. Moshkevich joined in 2011, most recently served as president of clinical diagnostics, and previously led the oncology expansion that includes Signatera. MarketWatch and Investing.com both tied the after-hours selloff to the combination of the EPS miss and the same-day leadership change, even as the revenue outlook improved.
A beat-and-raise that still sells off when profitability and leadership change on the same print is a familiar pattern in high-multiple diagnostics names: the Street can clear the top line and still reprice the path to earnings and who is steering it.
Sixteen Percent After Hours Past a Fourteen-Percent Monthly Chain
OptionSlam tracked a roughly 13.69% implied move on the November 20 monthly straddle into the report. Earnings Watcher listed NTRA among Thursday's after-close names with an implied move near ±13.8%. An after-hours print near $304 is about 16.4% below Thursday's $363.76 close and past those prepaid ranges; earlier prints near $284 and the extended-hours low near $276.26 would be closer to 22% to 24% gaps and sit further outside the monthly band. Delayed Cboe quotes are a reference for Friday's open rather than fills: spreads can be wide after a double-digit gap, after-hours stock prints can fade or extend, and equity options do not trade until 9:30 AM ET.
When a Guidance Raise Still Breaks the Prepaid Band
A name that gaps lower by about 16% to 22% after a revenue raise leaves short straddles and iron condors that collected the roughly 14% event premium under directional pressure into Friday's open, especially if the stock holds below the monthly lower break-even. Long puts that captured the after-hours move can still lose value once implied volatility resets, particularly if the open stabilizes inside the prepaid band after the initial gap. Call debit spreads that needed a clean beat-and-rally face a tape that sold the stock on the EPS miss and CEO swap anyway. Our implied volatility guide covers how post-earnings IV usually compresses, and the OCC options disclosure document explains the risks of standardized options, including assignment.
Sources
*By the OptionsPilot Editorial Team. Published November 5, 2026, 8:17 PM PT. This article is for education only and is not investment advice. Options involve risk and are not suitable for all investors.*
